BioCryst Pharmaceuticals
BCRX
BCRX
177 hedge funds and large institutions have $898M invested in BioCryst Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 57 increasing their positions, 57 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
0% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 57
3.97% less ownership
Funds ownership: 72.26% → 68.29% (-4%)
16% less call options, than puts
Call options by funds: $10.5M | Put options by funds: $12.4M
Holders
177
Holding in Top 10
3
Calls
$10.5M
Puts
$12.4M
Top Buyers
| 1 | +$24.7M | |
| 2 | +$19.4M | |
| 3 | +$11.9M | |
| 4 |
DM
Deerfield Management
New York
|
+$10.3M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$9.82M |
Top Sellers
| 1 | -$38.2M | |
| 2 | -$23.1M | |
| 3 | -$16.2M | |
| 4 |
Goldman Sachs
New York
|
-$8.69M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$7.82M |